1049809-52-0

Upstream product

• 42860-04-8 4-chloro-3-iodobenzoic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 217807-98-2 4-morpholin-4-yl-3,6-dihydro-2H-pyridine-1-carboxylic acid ter-tbutyl ester 
• 42860-17-3 4-chloro-3-iodo-benzoyl chloride 
• 1049809-51-9 3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]-pyridine-5-carboxylic acid tert-butyl ester 
• 107-13-1 acrylonitrile 

Downstream Products

• 1049809-75-7 3-(4-Chloro-3-iodo-phenyl)-1-(3-oxo-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements

A crystal structure of 1 bound to a Cys25Ser mutant of cathepsin S helped to elucidate the binding mode of a previously disclosed series of pyrazole-based CatS inhibitors and facilitated the design of a new class of arylalkyne analogs. Optimization of the

CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.